+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 151 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227802

Global Pancreatic Cancer Drugs Market to Reach $3.7 Billion by 2030

The global market for Pancreatic Cancer Drugs estimated at US$2.5 Billion in the year 2022, is projected to reach a revised size of US$3.7 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2022-2030. Exocrine, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$3.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endocrine segment is readjusted to a revised 3.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $684.6 Million, While China is Forecast to Grow at 8.2% CAGR

The Pancreatic Cancer Drugs market in the U.S. is estimated at US$684.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$791 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 5.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Select Competitors (Total 14 Featured) -

  • Amgen, Inc.
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • PharmaCyte Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Pancreatic Cancer Drugs

What is the estimated value of the Global Market for Pancreatic Cancer Drugs?

The Global Market for Pancreatic Cancer Drugs was estimated to be valued at $2.5 Billion in 2022.

What is the growth rate of the Global Market for Pancreatic Cancer Drugs?

The growth rate of the Global Market for Pancreatic Cancer Drugs is 5.0%, with an estimated value of $3.7 Billion by 2030.

What is the forecasted size of the Global Market for Pancreatic Cancer Drugs?

The Global Market for Pancreatic Cancer Drugs is estimated to be worth $3.7 Billion by 2030.

Who are the key companies in the Global Market for Pancreatic Cancer Drugs?

Key companies in the Global Market for Pancreatic Cancer Drugs include Amgen, Inc., Celgene Corporation, Clovis Oncology, Eli Lilly and Company, F. Hoffmann, La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer, Inc. and PharmaCyte Biotech, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Pancreatic Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Pancreatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Endocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Exocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Exocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Exocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Biologic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Biologic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Biologic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 19: World Pancreatic Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 22: USA 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: USA Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 25: USA 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 28: Canada 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 31: Canada 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
JAPAN
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 34: Japan 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 37: Japan 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
CHINA
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 40: China 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: China Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 43: China 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
EUROPE
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Pancreatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 46: Europe 18-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 49: Europe 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 52: Europe 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
FRANCE
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 55: France 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: France Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 58: France 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
GERMANY
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 61: Germany 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 64: Germany 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 67: Italy 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 70: Italy 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
UNITED KINGDOM
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 73: UK 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: UK Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 76: UK 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
SPAIN
  • Table 77: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Spain Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 79: Spain 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 80: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Spain Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 82: Spain 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
RUSSIA
  • Table 83: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: Russia Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 85: Russia 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 86: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Russia Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 88: Russia 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 91: Rest of Europe 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 94: Rest of Europe 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
ASIA-PACIFIC
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 97: Asia-Pacific 18-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 100: Asia-Pacific 18-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2012, 2023 & 2030
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 103: Asia-Pacific 18-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2012, 2023 & 2030
AUSTRALIA
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • PharmaCyte Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.